top of page

Janux's CEO David Campbell reviews this week's data from JANX007, the company's PSMA x CD3 masked bispecific for prostate cancer

  • blonca9
  • Dec 7, 2024
  • 1 min read

He describes how the improvement over data from earlier this year gives him confidence in the strength of the signal he sees in this data, the next steps ahead, what the data suggests about the overall platform, and how Janux thinks about business development.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page